Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres

[1]  S. Rajkumar,et al.  Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.

[2]  A. Oriol,et al.  Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma. , 2019, Blood.

[3]  H. Einsele,et al.  Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial , 2017, British journal of haematology.

[4]  B. Pégourié,et al.  VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. , 2016, Blood.

[5]  A. Palumbo,et al.  Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma , 2015, Leukemia.

[6]  D. Hose,et al.  Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma , 2015, Leukemia.

[7]  S. Trudel,et al.  CyBorD induction therapy in clinical practice , 2015, Bone Marrow Transplantation.

[8]  I. Flinn,et al.  Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. , 2012, Blood.

[9]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[10]  P. L. Bergsagel,et al.  Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. , 2010, Blood.

[11]  G. Morgan,et al.  The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. , 2007, Haematologica.